Review



cd47 polyclonal antibody  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Proteintech cd47 polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Cd47 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 78 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 polyclonal antibody/product/Proteintech
    Average 95 stars, based on 78 article reviews
    cd47 polyclonal antibody - by Bioz Stars, 2026-02
    95/100 stars

    Images

    1) Product Images from "Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics"

    Article Title: Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics

    Journal: Materials Today Bio

    doi: 10.1016/j.mtbio.2025.102414

    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) CD47 protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Figure Legend Snippet: Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) CD47 protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.

    Techniques Used: Expressing, In Vitro, Phagocytosis Assay, Fluorescence, Microscopy, Inhibition, Co-Culture Assay

    Antitumor effects of CRPIL/siCD47/siPLK1 complexes. (a). Expression of CD4 7 mRNA and PLK1 mRNA in 4T1 cells after different treatments. (b) The phagocytosis efficiency of J774A.1 cells against 4T1 cells after different treatments. (c) Schematic illustration of treatment schedule. (d) Changes in tumor volumes during the treatment. (e–f) Photographs of dissected tumors and average tumor weights at the end of the treatment. (g) Expression of CD47 and PLK1 proteins in tumor tissues after different treatments. (h) Representative images of hematoxylin and eosin-stained, TUNEL-stained and calreticulin (CRT)-stained tumor tissues on day 14.
    Figure Legend Snippet: Antitumor effects of CRPIL/siCD47/siPLK1 complexes. (a). Expression of CD4 7 mRNA and PLK1 mRNA in 4T1 cells after different treatments. (b) The phagocytosis efficiency of J774A.1 cells against 4T1 cells after different treatments. (c) Schematic illustration of treatment schedule. (d) Changes in tumor volumes during the treatment. (e–f) Photographs of dissected tumors and average tumor weights at the end of the treatment. (g) Expression of CD47 and PLK1 proteins in tumor tissues after different treatments. (h) Representative images of hematoxylin and eosin-stained, TUNEL-stained and calreticulin (CRT)-stained tumor tissues on day 14.

    Techniques Used: Expressing, Staining, TUNEL Assay



    Similar Products

    93
    R&D Systems anti cd47 polyclonal antibody
    Expression of <t>CD47</t> in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 <t>polyclonal</t> antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.
    Anti Cd47 Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd47 polyclonal antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti cd47 polyclonal antibody - by Bioz Stars, 2026-02
    93/100 stars
      Buy from Supplier

    94
    Bioss marker cd47
    <t>CD47</t> expression in striatal neurons of R6/2 mice. Confocal laser scanning microscopy images of double-label immunofluorescence for CD47 (visualized in red fluorescence) and the Nissl-like fluorescent marker Neurotrace (visualized in green fluorescence). (A–D) Images show the expression pattern of CD47 in the striatum of 5 and 13 weeks-old wild-type mice and in 5 and 13 weeks-old R6/2 mice. (E,F) Detail of cytoplasmic membrane CD47 expression in 13 weeks-old Wt mice. In 13 weeks-old R6/2 mice CD47 is lower due to cell death process (G) Histogram shows CD47 intensity quantification which is significantly decreased in the striatal neurons of 13 weeks-old R6/2 mice [Genotype effect F (1,153) = 11.97, *** P = 0.0007]. (H,I) Tukey’s multiple comparisons analysis revealed a significant protein decrease of striatal neuronal CD47, as evaluated by western blotting in R6/2 mice [Genotype effect F (1,20) = 8.667, ** P = 0.0080; Time effect F (1,20) = 5.802, ** P = 0.0258; Genotype X Time Interaction F (1,20) = 37.89, *** P < 0,0001].
    Marker Cd47, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/marker cd47/product/Bioss
    Average 94 stars, based on 1 article reviews
    marker cd47 - by Bioz Stars, 2026-02
    94/100 stars
      Buy from Supplier

    95
    Proteintech cd47 polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Cd47 Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 polyclonal antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    cd47 polyclonal antibody - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    95
    Proteintech polyclonal antibodies cd47
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Polyclonal Antibodies Cd47, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal antibodies cd47/product/Proteintech
    Average 95 stars, based on 1 article reviews
    polyclonal antibodies cd47 - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    Beyotime cd47 rabbit polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Cd47 Rabbit Polyclonal Antibody, supplied by Beyotime, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 rabbit polyclonal antibody/product/Beyotime
    Average 90 stars, based on 1 article reviews
    cd47 rabbit polyclonal antibody - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    96
    Bio X Cell invivomab anti mouse cd47 polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Invivomab Anti Mouse Cd47 Polyclonal Antibody, supplied by Bio X Cell, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/invivomab anti mouse cd47 polyclonal antibody/product/Bio X Cell
    Average 96 stars, based on 1 article reviews
    invivomab anti mouse cd47 polyclonal antibody - by Bioz Stars, 2026-02
    96/100 stars
      Buy from Supplier

    90
    ABclonal Biotechnology anti-cd47 rabbit polyclonal antibody a1838
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Anti Cd47 Rabbit Polyclonal Antibody A1838, supplied by ABclonal Biotechnology, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-cd47 rabbit polyclonal antibody a1838/product/ABclonal Biotechnology
    Average 90 stars, based on 1 article reviews
    anti-cd47 rabbit polyclonal antibody a1838 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    95
    Proteintech cd47 mouse polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Cd47 Mouse Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47 mouse polyclonal antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    cd47 mouse polyclonal antibody - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    95
    Proteintech gsdmd rabbit polyclonal antibody
    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) <t>CD47</t> protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.
    Gsdmd Rabbit Polyclonal Antibody, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/gsdmd rabbit polyclonal antibody/product/Proteintech
    Average 95 stars, based on 1 article reviews
    gsdmd rabbit polyclonal antibody - by Bioz Stars, 2026-02
    95/100 stars
      Buy from Supplier

    90
    Thermo Fisher polyclonal anti-cd47 antibody pa5-80435
    Representative example of <t>CD47</t> expression in soft tissue sarcomas. A leiomyosarcoma 0; no staining of tumor cells, B undifferentiated pleiomorphic sarcoma 1 + ; less than 1/3 of the total tumor area positive (focal positivity), ( C ) dedifferentiated liposarcoma 2 + ; 1/3 – 2/3 of the total tumor area positive (moderate positivity) and D myxofibrosarcoma 3 + ; more than 2/3 of the total tumor area positive (diffuse positivity). Image magnification was 40 × and scale bars indicate 50 μm
    Polyclonal Anti Cd47 Antibody Pa5 80435, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/polyclonal anti-cd47 antibody pa5-80435/product/Thermo Fisher
    Average 90 stars, based on 1 article reviews
    polyclonal anti-cd47 antibody pa5-80435 - by Bioz Stars, 2026-02
    90/100 stars
      Buy from Supplier

    Image Search Results


    Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Immunohistochemistry, Staining, Immunohistochemical staining

    Patient characteristics by pre-NACT  CD47  expression

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Patient characteristics by pre-NACT CD47 expression

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques:

    Expression of  CD47  in epithelial ovarian cancer tissues

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Immunohistochemistry

    Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Wilcoxon signed ranks test of the  CD47  expression pre- and post-NACT

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Wilcoxon signed ranks test of the CD47 expression pre- and post-NACT

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Multivariate prognostic analysis

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Multivariate prognostic analysis

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

    The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Control

    Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Fluorescence

    CD47 expression in striatal neurons of R6/2 mice. Confocal laser scanning microscopy images of double-label immunofluorescence for CD47 (visualized in red fluorescence) and the Nissl-like fluorescent marker Neurotrace (visualized in green fluorescence). (A–D) Images show the expression pattern of CD47 in the striatum of 5 and 13 weeks-old wild-type mice and in 5 and 13 weeks-old R6/2 mice. (E,F) Detail of cytoplasmic membrane CD47 expression in 13 weeks-old Wt mice. In 13 weeks-old R6/2 mice CD47 is lower due to cell death process (G) Histogram shows CD47 intensity quantification which is significantly decreased in the striatal neurons of 13 weeks-old R6/2 mice [Genotype effect F (1,153) = 11.97, *** P = 0.0007]. (H,I) Tukey’s multiple comparisons analysis revealed a significant protein decrease of striatal neuronal CD47, as evaluated by western blotting in R6/2 mice [Genotype effect F (1,20) = 8.667, ** P = 0.0080; Time effect F (1,20) = 5.802, ** P = 0.0258; Genotype X Time Interaction F (1,20) = 37.89, *** P < 0,0001].

    Journal: Frontiers in Cellular Neuroscience

    Article Title: Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington’s disease

    doi: 10.3389/fncel.2024.1360066

    Figure Lengend Snippet: CD47 expression in striatal neurons of R6/2 mice. Confocal laser scanning microscopy images of double-label immunofluorescence for CD47 (visualized in red fluorescence) and the Nissl-like fluorescent marker Neurotrace (visualized in green fluorescence). (A–D) Images show the expression pattern of CD47 in the striatum of 5 and 13 weeks-old wild-type mice and in 5 and 13 weeks-old R6/2 mice. (E,F) Detail of cytoplasmic membrane CD47 expression in 13 weeks-old Wt mice. In 13 weeks-old R6/2 mice CD47 is lower due to cell death process (G) Histogram shows CD47 intensity quantification which is significantly decreased in the striatal neurons of 13 weeks-old R6/2 mice [Genotype effect F (1,153) = 11.97, *** P = 0.0007]. (H,I) Tukey’s multiple comparisons analysis revealed a significant protein decrease of striatal neuronal CD47, as evaluated by western blotting in R6/2 mice [Genotype effect F (1,20) = 8.667, ** P = 0.0080; Time effect F (1,20) = 5.802, ** P = 0.0258; Genotype X Time Interaction F (1,20) = 37.89, *** P < 0,0001].

    Article Snippet: Coronal brain sections were incubated with the marker CD47 (BS-21460R, rabbit polyclonal anti-CD47, Bioss, USA) at 1:200 dilution in a 0.1 M PB solution containing 0.3% Triton X-100 for 72 h at 4°C.

    Techniques: Expressing, Confocal Laser Scanning Microscopy, Immunofluorescence, Fluorescence, Marker, Membrane, Western Blot

    Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) CD47 protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.

    Journal: Materials Today Bio

    Article Title: Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics

    doi: 10.1016/j.mtbio.2025.102414

    Figure Lengend Snippet: Antitumor effects of CRPIL/siCD47 complexes. (a) Expression of CD4 7 mRNA in 4T1 cells after different treatments. (b) Schematic illustration of in vitro phagocytosis assay. (c–d) Fluorescence microscope images and quantification of phagocytosis efficiency of J774A.1 cells against 4T1 cells. (e) Schematic illustration of in vitro tumor cell inhibition assay. (f) Cellular viability of 4T1 cells following various treatments in co-culture with J774A.1 macrophages. (g) Schematic illustration of siRNA treatment schedule. (h) Changes in tumor volumes during the treatment. (i–j) Dissected tumors and their average weights after treatment. (k) CD47 protein expression in tumor tissues across treatment groups. (l) Infiltration of CD86 + M1 macrophages in tumors following different treatments.

    Article Snippet: After washing, the membranes were incubated with CD47 Polyclonal antibody (Proteintech Group, 20305-1-AP), PLK1 Polyclonal antibody (Proteintech Group, 10305-1-AP) or GAPDH Monoclonal antibody (Proteintech Group, 60004-1-Ig) for 1 h at room temperature.

    Techniques: Expressing, In Vitro, Phagocytosis Assay, Fluorescence, Microscopy, Inhibition, Co-Culture Assay

    Antitumor effects of CRPIL/siCD47/siPLK1 complexes. (a). Expression of CD4 7 mRNA and PLK1 mRNA in 4T1 cells after different treatments. (b) The phagocytosis efficiency of J774A.1 cells against 4T1 cells after different treatments. (c) Schematic illustration of treatment schedule. (d) Changes in tumor volumes during the treatment. (e–f) Photographs of dissected tumors and average tumor weights at the end of the treatment. (g) Expression of CD47 and PLK1 proteins in tumor tissues after different treatments. (h) Representative images of hematoxylin and eosin-stained, TUNEL-stained and calreticulin (CRT)-stained tumor tissues on day 14.

    Journal: Materials Today Bio

    Article Title: Targeted biomimetic fusogenic liposome enhances tumor accumulation, penetration, and therapeutic efficacy of siRNA therapeutics

    doi: 10.1016/j.mtbio.2025.102414

    Figure Lengend Snippet: Antitumor effects of CRPIL/siCD47/siPLK1 complexes. (a). Expression of CD4 7 mRNA and PLK1 mRNA in 4T1 cells after different treatments. (b) The phagocytosis efficiency of J774A.1 cells against 4T1 cells after different treatments. (c) Schematic illustration of treatment schedule. (d) Changes in tumor volumes during the treatment. (e–f) Photographs of dissected tumors and average tumor weights at the end of the treatment. (g) Expression of CD47 and PLK1 proteins in tumor tissues after different treatments. (h) Representative images of hematoxylin and eosin-stained, TUNEL-stained and calreticulin (CRT)-stained tumor tissues on day 14.

    Article Snippet: After washing, the membranes were incubated with CD47 Polyclonal antibody (Proteintech Group, 20305-1-AP), PLK1 Polyclonal antibody (Proteintech Group, 10305-1-AP) or GAPDH Monoclonal antibody (Proteintech Group, 60004-1-Ig) for 1 h at room temperature.

    Techniques: Expressing, Staining, TUNEL Assay

    Representative example of CD47 expression in soft tissue sarcomas. A leiomyosarcoma 0; no staining of tumor cells, B undifferentiated pleiomorphic sarcoma 1 + ; less than 1/3 of the total tumor area positive (focal positivity), ( C ) dedifferentiated liposarcoma 2 + ; 1/3 – 2/3 of the total tumor area positive (moderate positivity) and D myxofibrosarcoma 3 + ; more than 2/3 of the total tumor area positive (diffuse positivity). Image magnification was 40 × and scale bars indicate 50 μm

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Representative example of CD47 expression in soft tissue sarcomas. A leiomyosarcoma 0; no staining of tumor cells, B undifferentiated pleiomorphic sarcoma 1 + ; less than 1/3 of the total tumor area positive (focal positivity), ( C ) dedifferentiated liposarcoma 2 + ; 1/3 – 2/3 of the total tumor area positive (moderate positivity) and D myxofibrosarcoma 3 + ; more than 2/3 of the total tumor area positive (diffuse positivity). Image magnification was 40 × and scale bars indicate 50 μm

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing, Staining

    Expression of CD47 molecule among various histological subtypes of soft tissue sarcoma (STS). A CD47 scale positivity in ( n = 55) and B frequency of CD47 scale positivity among grade (G)1 + G2 and G3. C CD47 scale positivity and D frequency in liposarcoma (LPS), myxofibrosarcoma (MFS) and undifferentiated pleiomorphic sarcoma (UPS) ( n = 47). E CD47 scale positivity ( n = 22) and F its frequency among G1 + G2 and G3 in LPS. G CD47 scale positivity in LPS divided according to histological subtypes. H frequency of CD47 scale positivity in myxofibrosarcoma (MFS) ( n = 11) and I its frequency between G1 + G2 and G3. J CD47 scale positivity in high-grade undifferentiated pleiomorphic sarcoma (UPS) ( n = 16). CD47 scale positivity indicators: 0 no staining of tumor cells, 1 + expression in less than 1/3 of tumor tissue, 2 + expression in 1/3 to 2/3 of tumor tissue, and 3 + expression in more than 1/3 of tumor tissue. p values were calculated using Mann–Whitney U test

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Expression of CD47 molecule among various histological subtypes of soft tissue sarcoma (STS). A CD47 scale positivity in ( n = 55) and B frequency of CD47 scale positivity among grade (G)1 + G2 and G3. C CD47 scale positivity and D frequency in liposarcoma (LPS), myxofibrosarcoma (MFS) and undifferentiated pleiomorphic sarcoma (UPS) ( n = 47). E CD47 scale positivity ( n = 22) and F its frequency among G1 + G2 and G3 in LPS. G CD47 scale positivity in LPS divided according to histological subtypes. H frequency of CD47 scale positivity in myxofibrosarcoma (MFS) ( n = 11) and I its frequency between G1 + G2 and G3. J CD47 scale positivity in high-grade undifferentiated pleiomorphic sarcoma (UPS) ( n = 16). CD47 scale positivity indicators: 0 no staining of tumor cells, 1 + expression in less than 1/3 of tumor tissue, 2 + expression in 1/3 to 2/3 of tumor tissue, and 3 + expression in more than 1/3 of tumor tissue. p values were calculated using Mann–Whitney U test

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing, Staining, MANN-WHITNEY

    Chi-square test of independence to assess the association between  CD47  expression and grade, metastases, and death

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Chi-square test of independence to assess the association between CD47 expression and grade, metastases, and death

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing, Sampling

    Chi-square test of independence to assess the association between CD47 expression  (CD47  3 + vs CD47 0–2 +) and grade, metastases, and death

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Chi-square test of independence to assess the association between CD47 expression (CD47 3 + vs CD47 0–2 +) and grade, metastases, and death

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing, Sampling

    Association between CD47 expression and clinical outcome of patients with soft tissue sarcoma (STS). Kaplan–Meier curves depict the association between CD47 and A overall survival (OS), B metastasis-free survival, and C progression-free survival (PFS) in patients divided according to CD47 scale positivity. Kaplan–Meier curves show D OS, E metastasis-free survival, and PFS in CD47 0–2 + and CD47 3 + patients. Censored patients have not experienced the event of interest (progression, metastasis, death) by the end of the study period. The small vertical lines serve as a visual cue to underscore the presence of censored observations. p values were calculated by log-rank test

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Association between CD47 expression and clinical outcome of patients with soft tissue sarcoma (STS). Kaplan–Meier curves depict the association between CD47 and A overall survival (OS), B metastasis-free survival, and C progression-free survival (PFS) in patients divided according to CD47 scale positivity. Kaplan–Meier curves show D OS, E metastasis-free survival, and PFS in CD47 0–2 + and CD47 3 + patients. Censored patients have not experienced the event of interest (progression, metastasis, death) by the end of the study period. The small vertical lines serve as a visual cue to underscore the presence of censored observations. p values were calculated by log-rank test

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing

    Cox proportional hazards model assessing the prognostic significance of  CD47  expression on overall survival (OS)

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Cox proportional hazards model assessing the prognostic significance of CD47 expression on overall survival (OS)

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing

    Cox proportional hazards model assessing the prognostic significance of  CD47  expression on progression-free survival (PFS)

    Journal: Journal of Cancer Research and Clinical Oncology

    Article Title: A comprehensive analysis of CD47 expression in various histological subtypes of soft tissue sarcoma: exploring novel opportunities for macrophage-directed treatments

    doi: 10.1007/s00432-024-05661-1

    Figure Lengend Snippet: Cox proportional hazards model assessing the prognostic significance of CD47 expression on progression-free survival (PFS)

    Article Snippet: Next, the tissue slides were stained with a polyclonal anti-CD47 antibody (PA5-80435, Thermo Fisher Scientific, Massachusetts, USA).

    Techniques: Expressing